Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 2656 to 2670 of 8929 results

  1. Hyperhidrosis: oxybutynin (ES10)

    Summary of the evidence on oxybutynin for treating hyperhidrosis (excessive sweating) to inform local NHS planning and decision-making

  2. Hypersexuality: fluoxetine (ESUOM46)

    Summary of the evidence on fluoxetine for treating hypersexuality to inform local NHS planning and decision-making

  3. Promoting tolerance of enteral feeds in children and young people: domperidone (ESUOM18)

    Summary of the evidence on domperidone to promote tolerance of enteral feeds in children and young people..

  4. Inflammatory lesions of papulopustular rosacea: ivermectin 10 mg/g cream (ESNM68)

    Summary of the evidence on ivermectin 10 mg/g cream for treating papulopustular rosacea to inform local NHS planning and decision-making

  5. Restless legs syndrome: Oxycodone/naloxone prolonged release (ESNM67)

    Summary of the evidence on oxycodone/naloxone prolonged release for treating restless leg syndrome (RLS) to inform local NHS planning and decision-making

  6. Premature ejaculation: dapoxetine (ESNM40)

    Summary of the evidence on dapoxetine for premature ejaculation to inform local NHS planning and decision-making

  7. Chronic anal fissure: 0.2% topical glyceryl trinitrate ointment (ESUOM7)

    Summary of the evidence on 0.2% topical glyceryl trinitrate ointment for chronic anal fissure to inform local NHS planning and decision-making

  8. External genital and perianal warts: green tea (Camellia sinensis) leaf extract 10% ointment (ESNM66)

    Summary of the evidence on green tea (Camellia sinensis) leaf extract 10% ointment for treating external genital and perianal warts to inform local NHS planning

  9. Pouchitis: rifaximin (ESUOM30)

    Summary of the evidence on rifaximin for treating pouchitis to inform local NHS planning and decision-making

  10. Chronic anal fissure: 2% topical diltiazem hydrochloride (ESUOM3)

    Summary of the evidence on 2% topical diltiazem hydrochloride for chronic anal fissure to inform local NHS planning and decision-making

  11. Ovarian cancer (advanced): bevacizumab 7.5 mg/kg in combination with paclitaxel and carboplatin for first-line treatment (ESUOM21)

    Summary of the evidence on bevacizumab 7.5 mg/kg with paclitaxel and carboplatin for the first-line treatment of advanced ovarian cancer..

  12. Mitochondrial disorders in children: Co-enzyme Q10 (ES11)

    Summary of the evidence on co-enzyme Q10 for mitochondrial disorders in children to inform local NHS planning and decision-making

  13. Erectile dysfunction: avanafil (ESNM45)

    Summary of the evidence on avanafil for treating erectile dysfunction to inform local NHS planning and decision-making

  14. Early and metastatic HER2-positive breast cancer: subcutaneous trastuzumab (ESNM13)

    Summary of the evidence on subcutaneous trastuzumab for HER2-positive breast cancer to inform local NHS planning and decision-making

  15. Erectile dysfunction: Alprostadil cream (ESNM50)

    Summary of the evidence on alprostadil cream for treating erectile dysfunction to inform local NHS planning and decision-making